Baricitinib Provides Holistic Improvement in Scalp, Eyebrow, and Eyelash Regrowth in Adolescents With Severe Alopecia Areata

In the BRAVE-AA-PEDS Phase 3 trial, baricitinib demonstrated efficacy in adolescents (12 to <18 years) with severe alopecia areata (AA), achieving holistic improvement in scalp, eyebrow, and eyelash regrowth over 52 weeks. More than 70% of patients had eyebrow and eyelash involvement at baseline. The majority of Week 52 scalp responders experienced significant regrowth across all three hair-bearing sites. Additionally, significant eyebrow and/or eyelash regrowth was observed even in those with partial or no scalp response to baricitinib. This holistic response may reduce the psychosocial burden of AA and enhance treatment satisfaction.